Meddenovo Drug Design
Ilke Ugur Marion is a highly skilled computational chemist with extensive experience in molecular modeling and drug design. As a Co-Founder and Managing Partner at Meddenovo Drug Design since July 2021, Ilke Ugur Marion leads innovative projects in the field. Additionally, Ilke has been a researcher since October 2018 at Middle East Technical University. Previous roles include freelance computational chemist and postdoctoral researcher at Technical University of Munich, focusing on protein-ligand interactions and water oxidation mechanisms. Education includes multiple Ph.D. degrees in Chemistry and Computational Chemistry from Boğaziçi University and Université de Lorraine, as well as a Master's degree and Bachelor's degree from Boğaziçi University.
This person is not in any teams
Meddenovo Drug Design
Meddenovo offers a unique blend of AI technologies and molecular modeling to increase efficiency and success in drug development processes. Our technological platform, including bioAIM and focAlyze, delivers unparalleled drug candidate potency assessment and optimization of drug-like properties. In addition to designing small organic molecules, our proficiency in peptide-based medicine and metal chelators extends beyond traditional boundaries, offering a competitive advantage in creating solutions for novel drug research and development studies. In our integrated drug discovery services, we create a unique chemical space specific to your biological targets. We use our focAIyze module to explore druggability or any specific physiochemical property your project might need of the created chemical space. With our physics-based AI-supported software bioAIM, we screen the target with great accuracy. bioAIM, utilizing its unique blind docking capability, reveals precise binding sites and gauges the potency of molecules, ensuring compatibility with complex entities such as DNA or ribosomes. We also provide custom computational solutions using our modular tools to predict drug resistance bound to mutations, elucidate biochemical reaction mechanisms, and calculate metal affinity analysis. Meddenovo strives for precision and reliability in drug discovery, providing a refined approach to developing groundbreaking medicines with reduced failure rates and improved outcomes.